Preeclampsia Drugs Global Market Report 2024

The global preeclampsia drugs market has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The global preeclampsia drugs market is expected to see rapid growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

The increasing incidence of diabetes among pregnant women is anticipated to drive the expansion of the preeclampsia drug market in the future. Diabetes is a chronic metabolic disease characterized by elevated levels of blood glucose, and it can lead to detrimental effects on pregnancy, including preeclampsia. Metformin, a medication used in the management of preeclampsia, finds significant application among pregnant women at risk of developing this condition. As of December 2022, data from the National Library of Medicine, a US-based biomedical library and informatics center, reported a total of 20,865 cases of gestational diabetes mellitus (GDM) in 2022, signifying a 6.56% increase. Consequently, the upsurge in diabetes cases among pregnant women is expected to be a driving force behind the preeclampsia drug market's growth.

The increasing prevalence of lifestyle diseases is poised to stimulate the expansion of the preeclampsia drugs market. Lifestyle diseases, also known as non-communicable diseases (NCDs), encompass a group of health conditions primarily attributed to unhealthy lifestyle choices and behaviors. Preeclampsia drugs are instrumental in treating lifestyle-related ailments such as hypertension, obesity, and diabetes, all of which represent risk factors for preeclampsia. For example, in September 2022, as reported by the World Health Organization, a specialized agency of the United Nations based in Switzerland, non-communicable diseases (NCDs) or chronic diseases accounted for 74% of the 41 million global annual deaths. This included 17.9 million deaths due to cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths related to chronic respiratory diseases, and 2.0 million deaths associated with diabetes. Consequently, the burgeoning prevalence of lifestyle diseases is a key driver behind the growth of the preeclampsia drugs market.

Insufficient investments act as a constraint and may impede the growth of the preeclampsia drugs market during the forecast period. The lack of financial support for preeclampsia drug development creates a substantial barrier for patients. It results in a restricted pipeline of new drug candidates, increased research costs, limited public funding, reduced access to treatments, heightened healthcare expenses, and a diminished quality of life for affected individuals. For example, in 2022, as reported by the National Library of Medicine, a biomedical library, insufficient funding has resulted in a scarcity of preeclampsia medications in the market. Less than 1% of the 153 candidates have reached the market for this indication, with less than 9% being recommended in international guidelines or incorporated into routine clinical practice. Consequently, the lack of investments presents a hindrance to the growth of the preeclampsia drug market.

Prominent companies operating in the preeclampsia medicine market are actively engaged in the development of advanced drug solutions to bolster their market presence. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical company, announced the FDA's approval of an investigational new drug (IND) application for CBP-4888, Comanche's unique siRNA therapy designed for preeclampsia treatment. CBP-4888 is a subcutaneously administered siRNA therapy that reduces the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. Excessive production of the sFLT1 protein in the placenta is the primary cause of preeclampsia, as it enters the mother's circulation. CBP-4888 has the potential to alleviate preeclampsia symptoms, including high blood pressure and organ damage, and may enable the safe extension of pregnancy.

In October 2022, Ginkgo Bioworks Inc., a US-based provider of advanced biological technology, acquired Zymergen Inc. for an undisclosed amount. This acquisition strengthens Ginkgo's platform by integrating essential automation and software capabilities while bringing a wealth of experience in diverse biological engineering. Zymergen Inc., a US-based biotechnology company specializing in preeclampsia treatments, complements Ginkgo's biotechnology portfolio.

Major players in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

North America was the largest region in the preeclampsia drugs market in 2023. The regions covered in preeclampsia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the preeclampsia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The main types of preeclampsia drugs are categorized into treatments for mild preeclampsia and severe preeclampsia. Mild preeclampsia is a medical disorder that can affect pregnant women, often appearing after the 20th week of pregnancy. Treatment options for preeclampsia include medications to lower blood pressure, corticosteroids, and anticonvulsant medication. These drugs can be administered through various routes, including the oral route and parenteral (injectable) route. They are available through different distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Preeclampsia drugs are utilized by various end-users, including hospitals, specialty clinics, diagnostic centers, and other relevant healthcare facilities.

This report provides preeclampsia drug market statistics, including preeclampsia drug industry global market size, regional shares, competitors with a preeclampsia drug market share, detailed preeclampsia drug market segments, market trends and opportunities and any further data you may need to thrive in the preeclampsia drug industry. This preeclampsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.